Disc Medicine · 14 hours ago
Senior Manager, Submission Management & Regulatory Operations
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematologic diseases. They are seeking a Senior Manager for Submission Management & Regulatory Operations to oversee regulatory submissions, maintain compliance, and support project teams in a dynamic hybrid work environment.
BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Responsibilities
Manage the coordination and publishing of submissions to regulatory Health Authorities in the appropriate format using Veeva RIM
Monitor submission timelines and proactively identify risks or delays, leveraging Veeva RIM dashboards and reporting tools for visibility and tracking
Maintain accurate, audit-ready records and metadata within Veeva RIM to support regulatory compliance and inspection readiness
Provide support to Regulatory Staff by processing submission objects and content plans within Veeva RIM, ensuring proper document formatting, and incorporating bookmarks and hyperlinks as required
Archive regulatory submissions and correspondences; process submission metrics and reports as necessary
Maintain regulatory tracking tools as needed
Maintain current knowledge of existing and emerging regulations, standards, or guidance’s related to electronic submission and publishing requirements
Coordinate with external partners for operational deliverables including support of publishing and/or Veeva RIM on and off boarding
Manage and resolve publishing-related issues encountered during validation as needed
Maintain regulatory submission tracking reports
Provide support in the development of standard operational procedures, work instructions, and systems to ensure regulatory compliance
Maintain clinical trial regulatory compliance tracking for ongoing development programs
Provide training and guidance to project team members on Veeva RIM functionality and best practices
Support the organization in maintaining a work environment focused on quality and that fosters learning, open communication, and teamwork
Assist in the development and refinement of submission templates and SOPs
Other duties as assigned
Qualification
Required
Bachelor's degree in Pharmaceutical, Biological or related field
Minimum of 7+ years' overall experience in the biopharmaceutical/biotech industry and 5+ years of direct experience with Regulatory Operations activities and regulatory submissions. NDA/MAA application experience is a plus
Demonstrated knowledge of best practices and proficient use of applications in managing submissions and preparing submission content, i.e., Veeva RIM, MS Word, Excel, SharePoint, SmartSheet, Adobe Acrobat with Toolbox Pharma plug-in, and Starting Point templates
Demonstrates strong project management skills and attention to detail
Proficient hands-on working experience with Veeva RIM Submissions and Submissions Archive applications is required. Other RIM suite applications a plus
Strong knowledge of eCTD structure, FDA/EMA submission requirements, document formatting standards, and eCTD QC activities
Ability to interpret and implement regulatory legislation and/or updates
Proven ability to effectively multi-task and work under tight deadlines; must possess excellent organizational skills
Excellent communication and interpersonal skills; must be self-motivated with eagerness to grow professionally and learn
Ability to work independently and manage multiple priorities in a fast-paced environment
Personal attributes include: flexibility and integrity, good judgment and decision-making skills, action- and results-oriented, collaborative and team-oriented
Occasional travel required, as needed
Benefits
Comprehensive benefits
Competitive compensation packages
Company
Disc Medicine
Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.
Funding
Current Stage
Public CompanyTotal Funding
$1.29BKey Investors
Hercules CapitalFrazier Life SciencesBain Capital Life Sciences
2025-10-21Post Ipo Secondary· $25M
2025-10-21Post Ipo Equity· $225M
2025-01-22Post Ipo Equity· $225.5M
Recent News
2026-01-13
2026-01-13
Company data provided by crunchbase